Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMIT IDegLira: Intensive metabolic intervention for T2D remission
NCT03862716Phase 3Completed
- Sponsor
- Population Health Research Institute
- Start
- Apr 2019
- Primary completion
- Jun 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Population Health Research Institute. Primary endpoint: Drug-free diabetes remission at 28 weeks. Started Apr 2019; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03862716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03862716.